Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 235 of 6351
-
New hope for tough-to-treat stroke? tirofiban tested in 516 patients
Disease control CompletedBranch atheromatous disease (BAD)-related stroke, characterized by subcortical single infarcts without severe stenosis of the large artery, but with a clear atherosclerotic mechanism, is now regarded as a separate stroke type. BAD is associated with early neurological deteriorati…
Phase 3 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug aims to tame scleroderma in major trial
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/Euro…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Radiation boost may help CAR-T fight bulky lymphoma
Disease control Recruiting nowThis is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New hope for breast cancer with limited spread: targeted therapy trial launches
Disease control Recruiting nowOLIGAMI trial is a multi-institutional, two-arm, open-label, randomized controlled phase III trial being conducted with the participation of 50 hospitals belonging to Japan Clinical Oncology Group. After the first registration, all patients will be performed in a 12-week, subtype…
Phase 3 • Sponsor: Tokyo Medical and Dental University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Can a vibrating wire reopen completely blocked heart arteries?
Disease control CompletedThis is a prospective and multicenter clinical investigation aiming to evaluate the safety and effectiveness of coronary crossing system for the treatment of patients with coronary chronic total occlusions.
Sponsor: Shanghai MicroPort Rhythm MedTech Co., Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New psoriasis pill TAK-279 shows promise in large trial
Disease control CompletedThe main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque psoriasis. Participants will be assigned to one of the 3 study treatments (TAK-279, apremilast (an approved treatment), or a placebo…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could everyday antioxidants be a weapon against ALS?
Disease control OngoingThe purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS). If validated by this study, providing over-the-counter anti-oxidan…
Phase 2 • Sponsor: Dallas VA Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New biosimilar aims to offer cheaper melanoma treatment
Disease control OngoingThe purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma.
Phase 3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could a psychedelic compound help smokers quit for good?
Disease control Recruiting nowThis is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at…
Phase 2 • Sponsor: Johns Hopkins University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New antibody drug shows promise for bulging eyes in thyroid disease
Disease control CompletedThis is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).
Phase 3 • Sponsor: Viridian Therapeutics, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a newer heart failure drug protect kidneys better than an older one?
Disease control CompletedSacubitril/valsartan is an established medication for heart failure. However, data still lags in its use in heart failure patients with chronic kidney disease. Sacubitril/valsartan is manufacturer-labeled for use in patients with eGFR \< 30 ml/min/1.73 m2 at an initial dose of 24…
Phase 2/3 • Sponsor: National Heart Institute, Egypt • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a nasal spray break through tough depression?
Disease control Recruiting nowThe goal of this naturalistic, open label, single arm intervention study is to investigate the effects of Esketamine in treating depression.The main aims to answer are: * to investigate whether Esketamine is effective when added to ongoing antidepressant treatment * to identify …
Phase 4 • Sponsor: Royal North Shore Hospital • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Inhaled treprostinil aims to slow lung decline in fibrosis trial
Disease control Recruiting nowStudy RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.
Phase 3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Can a new biologic boost standard brain cancer therapy?
Disease control OngoingThe main objective of this clinical study is to evaluate the safety of XS005 injection; to determine the maximum tolerated dose . Furthermore, initial efficacy will be examined.
Phase 1/2 • Sponsor: Dushu Lake Hospital Affiliated to Soochow University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New targeted pill shows promise for Hard-to-Treat pancreatic cancer
Disease control Recruiting nowPatients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Phase 2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug T-DXd could outperform standard chemo in HER2+ breast cancer
Disease control Recruiting nowThe goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer. The main questions it aims to answer are: * is T-DXd more effective than standard preoperative treatment? …
Phase 2 • Sponsor: Karolinska University Hospital • Aim: Disease control
Last updated Jun 26, 2026 13:06 UTC
-
Immunotherapy-Chemo combo aims to make inoperable esophageal cancer removable
Disease control OngoingThe goal of this trial is to test the efficacy and safety of cardenilimab combined with chemotherapy in the conversion therapy of locally advanced unresectable esophageal squamous cell carcinoma. type of study: clinical trial
Phase 2 • Sponsor: Li Zhang • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New hope for tough lymphoma: glofitamab takes on relapsed mantle cell cancer
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a new biologic drug shrink advanced melanoma tumors?
Disease control Recruiting nowThis is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
Phase 2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Liver pump chemotherapy may boost survival in advanced colorectal cancer
Disease control Recruiting nowThis phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be remo…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC